In this regard, the importance of the mitochondrial citrate carrier (SLC25A1) has recently emerged in tumor progression, cancer stemness, and resistance to therapy; additionally, the specific SLC25A1 inhibitor benzenetricarboxylate (BTA) has been proven to exert a promising anticancer activity [8,9,10]. This evidence concerns the gene SLC25A1 and neoplasm.